Trends and variation in andexanet alfa for the reversal of direct oral anticoagulants in NHS Trusts in England

Competing Interest Statement

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare the following: BG has received research funding from the Laura and John Arnold Foundation, the NHS National Institute for Health Research (NIHR), the NIHR School of Primary Care Research, the NIHR Oxford Biomedical Research Centre, the Mohn-Westlake Foundation, NIHR Applied Research Collaboration Oxford and Thames Valley, Wellcome Trust, the Good Thinking Foundation, Health Data Research UK, the Health Foundation, the World Health Organisation, UKRI, Asthma UK, the British Lung Foundation, and the Longitudinal Health and Wellbeing strand of the National Core Studies programme; he also receives personal income from speaking and writing for lay audiences on the misuse of science. AT acknowledges support from the National Institute of Health Research (NIHR) Oxford Health Biomedical Research Centre (BRC-1215-2000) and the NIHR Applied Research Collaboration (ARC) Oxford and Thames Valley. BMK, RC, VS , CW, AB work for the NHS and are seconded to the Bennett Institute. All other University of Oxford authors are employed on BG grants. VS has received speaker fees from Bayer. R.J.B. is a named investigator on an externally sponsored research grant from AstraZeneca to audit real-world use of reversal agents for DOACs across the UK.

Funding Statement

This work was supported by The NIHR Biomedical Research Centre, Oxford, A Health Foundation grant (Award Reference Number 7599); A National Institute for Health Research (NIHR) School of Primary Care Research (SPCR) grant (Award Reference Number 327); the National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant Reference Number PB-PG-0418-20036) and by the National Institute for Health Research Applied Research Collaboration Oxford and Thames Valley. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR, NHS England or the Department of Health and Social Care. Funders had no role in the study design, collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. The development of the OpenPrescribing Hospitals software has been funded by the NHS Primary Care and Medicines Analytics Unit.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes